Article
Vertex and Covid-19 spell the end for Savara's CF program
Rating:
0.0
Views:
142
Likes:
1
Library:
1
It's a tough market for cystic fibrosis these days. Just ask Savara. Two years ago, the Austin-based biotech designed and launched a trial to test whether their lead GM-CSF drug molgradex can reduce lung infection in adult CF patients. At the time, Vertex only had 3 CF drugs, they only
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value